• Red Light Holland's Sarah Hashkes' article titled "A Precise Definition of Microdosing Psychedelics is Needed to Promote Equitable Regulation" is currently available on the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School's online platform

• Hashkes to participate in an Online Webinar, A Macro View of Microdosing, with Industry Leaders on April 13th, 2022 organized by Harvard's Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School aiming to advance evidence-based psychedelics law and policy

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of a premium brand of magic truffles, is pleased to announce Sarah Hashkes, the company's Chief Technology and Innovation Officer (CTIO) will be participating in Harvard Law School's online webinar and symposium titled 'A Macro View of Microdosing'. The online webinar scheduled for April 13, 2022, 12:30 PM EDT will gather experts on the science, law, and business of microdosing for a panel discussion accompanied by a digital symposium on the Bill of Health, Harvard's online platform for readers interested in news, commentary, and scholarship in the fields of health law policy, biotechnology, and bioethics. After a keynote address by Dr. James Fadiman, a longtime microdosing scholar and advocate, the event will turn to a panel discussion of the promise, risks, and future of microdosing psychedelics.

"This is a great initiative I'm proud to be part of," said Sarah Hashkes, CTIO of Red Light Holland. "I'm excited to be able to share my expertise on the intersection of psychedelic science, commerce, and regulations with these expert thought leaders. I hope to share some of the anonymized information our users of Red Light Holland's iMicroapp consented to share as well as our market research data from Oregon and a review of the latest scientific publications around microdosing - all in hopes of promoting responsible legal access to naturally occurring Psilocybin."

"Red Light Holland is extremely grateful for all of Sarah Hashkes' hard work. Our iMicro App which collects consensual data, including usage, dosage and biometric movement data of end consumers of Red Light Holland's products in The Netherlands is essential to learn about people's actual experiences with microdosing. It's great that Sarah will get to share our preliminary findings, unique voice and self-regulatory approach to responsible use and legalization with other respected industry leaders and an intrigued online audience," said Todd Shapiro, CEO and Director of Red Light Holland. "We are also grateful for Harvard's Project on Psychedelics Law and Regulation for facilitating these important discussions and promoting expert knowledge on microdosing."

The event is organized by Harvard's Project on Psychedelics Law and Regulation (POPLAR), a three-year initiative to examine the ethical, legal, and social implications of psychedelics research, commerce, and therapeutics. Launched in summer 2021 with a generous grant from the Saisei Foundation, the Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School aims to advance evidence-based psychedelics law and policy.

Sarah Hashkes's article titled "A Precise Definition of Microdosing Psychedelics is Needed to Promote Equitable Regulation" can be found at this link: https://blog.petrieflom.law.harvard.edu/2022/04/05/microdosing-psychedelics-definition/

To register for the Harvard's Project on Psychedelics Law and Regulation (POPLAR) free online webinar go to: https://events.r20.constantcontact.com/register/eventReg?oeidk=a07ej1bbcdn85bb5c3f&oseq=&c=&ch=

About Red Light Holland

Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles.

For additional information on the Company

Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-TRIP (8747)
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Website: www.RedLight.co 

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward Looking Information

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the ability of the Company to deliver products to retail shops; the safety of the Company's products; the uses and potential benefits of the Company's products; the Harvard Law School's Online webinar, keynote address, and the ensuing panel discussion proceeding as scheduled; and the CTIO of the Company to be able to attend and present the webinar to promote the responsible legal access to naturally occurring Psilocybin.

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: continued approval of the Company's activities by the relevant governmental and/or regulatory authorities; the continued growth of the Company; the Company meeting their anticipated timeline and process for growth, sales, production and commercialization; the Company's products being safe and providing their anticipated benefits; the Harvard Law School's Online webinar, keynote address, and the ensuing panel discussion proceeding as scheduled; and the CTIO of the Company to be able to attend and present the webinar to promote the responsible legal access to naturally occurring Psilocybin.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company's operations; competition within the markets that the Company operates in; risks with respect to the safety of the Company's products; the risk that there is no potential benefit of the Company's products; risk that the Company will be unable to develop its products; risk that the Harvard Law School's Online webinar, keynote address, and ensuing panel discussion will be canceled or rescheduled; and risk that the CTIO of the Company to be unable to attend and present the webinar and/or unable to promote the responsible legal access to naturally occurring Psilocybin.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.